We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+19.15%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.86B
AUM Growth
+$577M
Cap. Flow
+$413M
Cap. Flow %
22.17%
Top 10 Hldgs %
49.85%
Holding
103
New
20
Increased
27
Reduced
19
Closed
9

Top Buys

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$21.4M
2
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$20.5M
3
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
+$16M
4
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$14.4M
5
ADXS
Advaxis Inc
ADXS
+$13.6M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$68.3M
2
TVTX icon
Travere Therapeutics
TVTX
+$21.9M
3
UAM
Universal American Corp
UAM
+$12.1M
4
AMPH icon
Amphastar Pharmaceuticals
AMPH
+$11.1M
5
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 75.61%
2 Technology 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCTL
26
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$18.3M 0.98%
1,576,089
– –
SPPI
27
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$18.1M 0.97%
2,650,000
+1,850,000
+231% +$11.7M
ZGNX
28
DELISTED
Zogenix, Inc.
ZGNX
$18M 0.97%
1,342,206
– –
DVAX
29
DELISTED
Dynavax Technologies
DVAX
$17.9M 0.96%
766,010
– –
CPRX
30
DELISTED
Catalyst Pharmaceutical
CPRX
$17.3M 0.93%
4,183,177
+100,000
+2% +$399K
PETX
31
DELISTED
Aratana Therapeutics, Inc.
PETX
$17.1M 0.92%
1,131,865
– –
IOVA icon
32
Iovance Biotherapeutics
IOVA
$2.26B
$16.6M 0.89%
1,812,419
+750,000
+71% +$8.37M
DSCI
33
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$16.6M 0.89%
2,317,489
+187,012
+9% +$1.41M
ATRS
34
DELISTED
Antares Pharma, Inc.
ATRS
$15.8M 0.85%
7,575,000
+2,875,000
+61% +$6.97M
ZVRA icon
35
Zevra Therapeutics
ZVRA
$563M
$15.2M 0.82%
+51,738
New +$11.3M
TLGT
36
DELISTED
Teligent, Inc
TLGT
$14.4M 0.77%
228,773
+128,773
+129% +$8.71M
CYNA
37
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$13.9M 0.75%
+878,117
New +$14.4M
GNCA
38
DELISTED
Genocea Biosciences, Inc.
GNCA
$13.7M 0.74%
124,595
-4,780
-4% -$444K
PRTK
39
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$13.7M 0.73%
530,283
+270,000
+104% +$7.66M
ATRC icon
40
AtriCure
ATRC
$1.7B
$11.9M 0.64%
483,354
-50,000
-9% -$1.12M
ANTH
41
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$11.8M 0.63%
171,307
-131,250
-43% -$6.08M
MRTX
42
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$11.3M 0.61%
359,661
+53,198
+17% +$1.57M
ELOS
43
DELISTED
Syneron Medical Ltd
ELOS
$10.7M 0.57%
1,005,221
– –
ARCT icon
44
Arcturus Therapeutics
ARCT
$161M
$10.3M 0.56%
225,687
+3,399
+2% +$156K
ADMA icon
45
ADMA Biologics
ADMA
$1.9B
$8.93M 0.48%
964,193
– –
ARDX icon
46
Ardelyx
ARDX
$1.25B
$8.88M 0.48%
+649,290
New +$8.19M
TRVN
47
DELISTED
Trevena, Inc.
TRVN
$8.82M 0.47%
2,255
– –
AMRN
48
Amarin Corp
AMRN
$285M
$8.67M 0.47%
176,261
+126,667
+255% +$5.7M
KALV
49
DELISTED
KalVista Pharmaceuticals
KALV
$8.43M 0.45%
+84,210
New +$8.36M
FATE icon
50
Fate Therapeutics
FATE
$287M
$8.41M 0.45%
1,300,000
+1,229,572
+1,746% +$7.36M
1
2
3 4 5

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Broadfin Capital held 103 positions worth $1.86B, up 45% from $1.28B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Broadfin Capital deployed $413M of net new capital in Q2 2015, opening 20 new positions and adding to 27 existing holdings. Its largest new stake was NEVRO CORP.: 419,559 shares worth $22.6M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 92% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $68.3M trimmed.

  • Broadfin Capital's largest Q2 2015 buy was NEVRO CORP.: 419,559 shares worth $22.6M.
  • Broadfin Capital added most to Pernix Therapeutics Holdings, Inc. in Q2 2015, an estimated $20.5M increase.
  • Broadfin Capital's biggest Q2 2015 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $68.3M.
  • Broadfin Capital fully exited Universal American Corp in Q2 2015, selling an estimated $12.1M.
  • Broadfin Capital's ten largest holdings make up 50% of its $1.86B portfolio in Q2 2015.
  • Broadfin Capital opened 20 new positions and closed 9 in Q2 2015.
  • Broadfin Capital's portfolio value rose 45% quarter-over-quarter to $1.86B.

Based on Broadfin Capital's 13F filing for Q2 2015, filed 14 Aug 2015.